Hassan Niam Whiteside, the American center for CBA champions Shanghai Sharks, is facing a potential two-year ban after a reported anti-doping violation linked to the 2025-26 Chinese Basketball Association playoffs.

According to the China Anti-Doping Agency, Whiteside tested positive for the prohibited substances oxandrolone metabolites and clomifene during a home playoff game against Shandong on May 6. The report also says he waived his right to a B-sample test, a step that leaves the original finding in place.

The reported substances are significant under the World Anti-Doping Agency prohibited list. Oxandrolone metabolites fall under anabolic agents, while clomifene is classified as a hormone and metabolic modulator. That classification explains why the case has quickly moved beyond a routine administrative issue and into the category of a potentially serious sanction.

The South China Morning Post report said any punishment for Whiteside would not include Shanghai being stripped of its title. That detail matters because the Sharks went on to win the championship despite Whiteside’s later absence from the finals.

The timeline is also notable. Whiteside played again in Shanghai’s quarter-final series after the positive test was recorded, and he appeared throughout the semi-final against the Beijing Ducks. He then missed the finals against Zhejiang Lions, which Shanghai won 4-1 to secure the title.

Whiteside, 37, arrived in China after an NBA career that ran from 2010 to 2022 with the Sacramento Kings, Portland Trail Blazers and Utah Jazz. The report also noted earlier stops in Lebanon and Puerto Rico before he joined Shanghai last year.

For Shanghai, the case creates an awkward mix of championship success and regulatory scrutiny. The team can keep the trophy, but the positive test casts a shadow over the final stretch of its season and over the role one of its highest-profile foreign players played in the campaign.

For Whiteside, the immediate question is whether the reported violation becomes a formal suspension and, if so, how long it lasts. The report frames a possible two-year ban, but the final outcome will depend on the anti-doping process that follows the agency’s finding.

The case also shows how anti-doping findings can affect a championship season without necessarily rewriting the standings. Shanghai’s title remains intact, but the player’s situation creates uncertainty around the season’s narrative and around any future availability he may have for the club.

Because Whiteside waived the B-sample test, the reported A-sample result carries more immediate importance. The article does not supply a formal sanction yet, but it is clear that the process has moved into a serious phase with potential consequences for the player’s career.

The report leaves open how long the case will take to resolve, but the immediate implication is clear: one of Shanghai’s most prominent foreign players is now tied to a formal anti-doping dispute rather than just a championship season. In professional basketball, that can shape both public perception and roster planning.

For readers of the Chinese basketball season, the key point is that the report separates the team’s championship from the player’s test result. The title can stand, but the anti-doping file now shapes the next chapter of Whiteside’s career.